Chinese-backed drug firm Gland Pharma has received a crucial nod from market regulator SEBI to launch an initial public offering (IPO) worth Rs 6,000 crore. 4. He is a Qualified Chartered Accountant and Company Secretary with Associate Membership of the respective institutes. by Healthcare Radius June 08, 2020. How good are your current hold decisions? 434.8 crores (56.5%) on working capital requirements, and Rs. Annual Report 2019-20 Gland Pharma Limited RISK MANAGEMENT COMMITTEE Mr. Dongming Li, Chairman Mr. Srinivas Sadu Mr. Ravi Shekhar Mitra STAKEHOLDERS’ RELATIONSHIP AND SHARE TRANSFER COMMITTEE KEY CONTACT Mr. Moheb Ali Mohammed, Chairman Mr. Udo Johannes Vetter Mr. Satyanarayana Murthy Chavali Mr. Dongming Li CORPORATE SOCIAL RESPONSIBILITY … Gland Share Price, Gland Stock Price, Gland Pharma Ltd. Stock/Share prices, Gland Pharma Ltd. Live BSE/NSE, F&O Quote of Gland Pharma Ltd. with Historic price charts for NSE / BSE. A manufacturing base with installed capacity of 750 million units per annum spread over seven facilities; proven Research and Development wing; pan-India and global distribution and sales network; affiliation with national and state level healthcare institutions; compliance with all necessary regulatory boards; and a high level of approvals and pending filings in our area of operations, all contribute to our standing in the pharma domain. The issue was subscribed by 2.06 times. Gland Pharma Limited – Company Overview. (3 new), Bajaj Finance: Poised to Exit Stronger Post Pandemic, Covid vax pricing to help govts curb out-of-pocket costs for people: Pfizer, Results Declared in Last Two Days with both YoY and QoQ Profit Growth, MFs for your child's education or retirement, Create your own screener (from 1000+ indicators), Shareholding screeners for promoters, MFs, institutions, Trending Today: Stocks with Highest Dividend Yields, Technical Screeners (RSI, MFI, EMA/SMA and more), Just getting started? This presence across the value chain has helped us witness exponential growth. 2,044 crores, respectively. 19.2 per share. In that time, the injectable market has grown at a CAGR of 10.1%, to $432 billion (Rs. 413 crores and the quarterly EBITDA margin was 46.7%. Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. Member of the International Leadership Forum (ILF) and the International Society for Pharmaceutical Engineering (ISPE); Dr. Penmetsa is also one of Fosun’s Global partners and the Chief Representative in India. The issue turned deadly in June this year when 20 Indian soldiers died, souring the ties between two neighbouring countries. At a time of such seismic shifts in the pharma industry, Gland Pharma, a Chinese-owned Indian pharmaceutical company is launching its IPO. Join to Connect Gland Pharma Limited ... Director & CEO, KP Energy Limited - Renewable Energy Project Developer Surat. Plans are underway to augment the present manufacturing capacity of approximately 750 million units in the medium term to support future growth. We operate primarily under a business to business (B2B) model and have an excellent track record in the development, manufacturing and marketing of complex injectables. View Gland Pharma (www.glandpharma.com) location in Telangana, India , revenue, industry and description. 57 crores (33.9%) on CAPEX, FY22: Rs. Fosun International, a Chinese conglomerate owns a majority stake in the company, which it acquired from private equity firm KKR in 2017 for $1.1 billion (~Rs. Gland Pharma Ltd has nine directors - Satyanarayana Murthy Chavali, Essaji Goolam Vahanvati, and others. Gland Pharma IPO: Share allotment finalised, here's how to check India has emerged as Instagram's crucial market, says CEO Adam Mosseri Loan disbursement by NBFC-MFIs dips 43% to … 101 lakh crores). Gland Pharma's IPO consists of up to 34.9 million secondary shares from existing shareholders, according to the terms. The net proceeds from the offering will be used for two purposes -- Rs. Add your portfolio to get detailed insights, Portfolio NAV: The true performance of your portfolio, Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation, Coal India plans to substitute 80-85 mt of imported coal in current fiscal, Pawan Munjal's Covid mantra: every crisis is an opportunity, don't waste it, Diversified base offers several growth opportunities for Jubilant FoodWorks, TATA MOTORS LTD. - 500570 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation, Copper in unchartered territory as prices hit lifetime high, Buy Navin Fluorine; target of Rs 3040: ICICI Direct, Burger King shares take first fall, hit 10% lower circuit after rallying 265%, Mrs. Bectors Food Specialities: More than a biscuit maker, Pharma and IPO winners and losers, Reliance loses some shine, Bajaj Finance poised to exit the pandemic stronger, Bajaj Auto: Pent-up demand gives way to reality. 111 crores (66.1%) on CAPEX. Shanghai Fosun Pharma, the company’s promoter, has experience in manufacturing, distribution, and R&D, with presence in China and Africa, key growth markets for Gland Pharma. With the larger market recovering, pharma companies revealing strong quarterly growth despite supply-side issues, and a global move to ‘de-risk’ away from China towards India, will this Chinese-promoter owned pharmaceutical company compliment the bullish pharma trend, or fall flat? Its finished dosage formulations (FDFs) facilities are located in Dundigal, Pashamylaram around Hyderabad, and the oncology facility in Visakhapatnam, while its active pharmaceutical ingredient (API) facilities are present in Visakhapatnam and Dundigal. The company in the last 3 years has generated a free cash flow of ~900 Crores. 5. Post the IPO, the promoter’s shareholding will drop to 58.4%, and the other shareholders will hold around 10.5% of the company. The IPO is broken down into a fresh issue of 83 lakh shares amounting to Rs. New Delhi: Gland Pharma, which closed its initial public offer (IPO) last week, has finalised the basis of allotmenr of shares in the IPO.Listing of its shares on exchanges is expected to happen on November 20 (Friday). BSE India A major factor in this offering is the company’s promoter, which is putting up part of its stake in the company via the offer for sale. Over the years, we have been able to move ahead on both those counts, to establish a presence across the entire value chain in Injectables. 955 crores, growing by 35% from FY19, while EBITDA margin was 36.3%. The funds will be deployed as follows. Gland Pharma’s total income for FY20 stood at Rs. Around 47% of this growth is expected to come from North America, while India and China will contribute 2% and 9% respectively. Fosun Pharma is planning to divest as many as 19.4 million shares in the IPO, while Gland Celsus Bio Chemicals Pvt., Empower Discretionary Trust and Nilay Discretionary Trust are selling 15.5 million shares in total. Beginning his career in Marketing at Smith Kline Beecham USA, he holds MS qualifications in Industrial Pharmacy from Long Island University, New York; MBA from University of Maryland, Baltimore; and postgraduate certification in Finance and Management from London School of Business and Finance. Since all the conditions p The shares is now available at Rs 120 in the grey market as on November 17, compared to the IPO price of Rs 1,500, Moneycontrol reported. With an MBBS from Osmania University, India and Science of Medicine from East Carolina, University School of Medicine, USA, where he continued in hospital-based practice for seven years, Dr. Penmetsa joined Gland Pharma as Executive Director, in 1992. With Indian pharmaceutical companies importing close to 70% of active pharmaceutical ingredients (APIs) from China, this global movement has forced domestic drug makers like Divi’s Labs, Aarti Drugs, Jubilant Life Sciences, and Granules India to alter supply chains. Gland Pharma’s business is focused on generic injectables, operating under a B2B model in over 60 countries including in the United States, Canada, Australia, India, and several European countries. 769.5 crores to fund incremental working capital requirements and Rs. We are promoted by Shanghai Fosun Pharma, a global pharmaceutical major. He has over 20 years’ experience in leading Financial Management, FP&A, Strategic Planning, Investor Relations in Pharmaceutical and other industries. The shareholding of the company before the IPO is as follows. India's biggest pharma IPO, Gland Pharma attracted a muted response from retail investors during the bidding process, but it got reversed after the festive occasion of Diwali. FY20 closed with a PAT of Rs. 29.1 per share. Gland Pharma IPO allotment status: Two ways to check on BSE and Link Intime India The Initial Public Offer (IPO) of Rs 6500 cr of Gland Pharma received good response from the investors. 47.3 per share (15.5 crore equity shares and 83 lakh fresh issue), Gland Pharma’s P/E ratio comes to 31.7 times. Over the past year, the importance of the Indian pharmaceutical industry has been emphasized like no other. China’s Fosun Pharma to bypass India’s regulatory hurdles after cutting stake in Gland Pharma deal Advertisement Wu Yifang, president and CEO of Shanghai Fosun Pharmaceutical Group. He has over 20 years of varied experience in International Business Development, Alliancing, Production, Engineering, Product Development and Supply Chain Management. However, taking the fresh issue of 83 lakh shares into account, the EPS for FY20 stands at Rs. Stocks to watch today on November 20: RIL, Gland Pharma, SBI, Alkem Labs, Bharti Infratel, Wipro, Infopsys among others are the top stocks to watch out for in Friday's trading session 314 crores, a 71% growth against the year-ago period. As of March 2020, Gland Pharma, with its partners, had 265 ANDAs (abbreviated new drug applications) pending in the US, with 204 approvals. Directors of Gland Pharma Ltd are Udo Jahannes Vetter, Yiu Kwan Stanley Lau, Satyanarayana Murthy Chavali, Srinivas Sadu, Li Dongming, Essaji Goolam Vahanvati, Moheb Ali Mohammed, Qiyu Chen, Xiaohui Guan, Yiran Peng, . In FY18 and FY19, its total income stood at Rs. Covid-19, global lockdowns curtailing supply, and de-risking away from China have pushed global demand towards India. The ability to provide therapeutic medicines on the best quality parameters and at the right price, is the overriding objective for us at Gland Pharma. Experienced management and parent company: Top-management including the CEO, CFO, and CTO have been with the company for over two decades. The NPM has also improved from 20% to 36%. Find related and similar companies as well as employees by title and much more. Out of the 265 filings, 189 were for sterile injectables, 50 for oncology, and 26 for ophthalmics-related products. It's EBITDA has increased by 35.62 % over the previous year. : Walkthrough for screener creation, backtesting, New superstar addition: Sunil Singhania's Abakkus. 49.8 per share for FY20, a rise of 71.1% from the previous year’s EPS of Rs. ASIAN PAINTS LTD. - 500820 - Compliances-Reg. They were established in Hyderabad, India in 1978 and have expanded from liquid parenterals to cover other elements of the injectables value chain, including contract development, own development, dossier preparation and filing, technology transfer and manufacturing across a range of delivery systems. Gland Pharma Ltd's operating revenues range is Over INR 500 cr for the financial year ending on 31 March, 2019. 2,633 crores, a growth of 29% on a yearly basis. At the same time, it's book networth has increased by 18.74 %. Gland Pharma, along with its partners MAIA Pharmaceuticals and Athenex Pharmaceutical Division announce the launch of a Ready-to-Use (RTU) Bivalirudin Injection in the United States of America. A closer look at Gland Pharma Hong Kong-listed Fosun acquired around 74 percent in Gland Pharma for around $1.09 billion in October, 2017, offering an exit to private equity firm KKR. The CAGR growth is approximately 27% in revenue and 55% in PAT. Gland Pharma has shown excellent growth in both topline and bottom line in the last 3 years. Gland Pharma is set to be India’s largest pharma public offering, with an issue size of Rs. 1,620 crores and Rs. 1,500, which values the IPO at Rs. 1,490 to Rs. 6,436.3 crores to Rs. Chinese drug firm Fosun Pharma has acquired approximately 74 per cent in Hyderabad-based Gland Pharma at a valuation of not more than USD 1.09 billion, the company has said. Mr Mitra joined Gland Pharma as CFO in 2019. North America contributed 55% of the injectable market, followed by Europe (20%), China (11%), India (1%), and the remaining 13% from the rest of the world (most prominently Japan, Russia, South Korea, and Russia). The share of retail investors got subscribed 24%, while the share on non-institutional investors got subscribed 51%. The issue size is a total of 43.1 crore shares, at a price band of Rs. Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. 47.3 per share, and the EPS for Q1FY21 at Rs. The company’s manufacturing capacity for FDF products stood at 755 million units per annum at the close of the previous fiscal year. The Indian government blocked many Chinese apps, increased scrutiny of Chinese … The injectable market, in which Gland Pharma finds its niche, is the second-largest form of drug delivery, accounting for 39% of the global pharmaceutical market value in 2019, up from 32% in 2014. 168 crores for CAPEX. With over 38 years’ experience in Quality Assurance, Quality Control and Regulatory Affairs, Mr Raju holds a Master of Science in Organic Chemistry and Post Graduate Diploma in Industrial Microbiology. Gland Pharma announces launch of the first novel non-frozen ready-to-use Bivalirudin This is the first non-frozen ready-to-use bivalirudin 505b(2) NDA approved by the USFDA . Here’s how Gland Pharma’s valuation compares to listed pharmaceutical peers. 1,250 crores and an offer for sale (OFS) of 3.4 crore equity shares by the promoters and other selling shareholders. All other factors remaining equal, backward integration and economies of scale play a significant role in providing quality medications at the right price. Mr Raju’s association with the company goes back since its inception and he has closely been connected in putting into place quality control norms and practices as envisaged by our founder. The company is debt-free. Gland Pharma seeks lock-in exemption for shares owned by Ex Satyam CEO Ramanlinga Raju. The four-decade-old Hyderabad-based pharmaceutical company has seven manufacturing facilities throughout the country. Profit after tax (PAT) has more than doubled between FY18 to FY20, with a CAGR of 55.1%. The book running lead managers (BRLMs) to the issue are Kotak Mahindra Capital, Citigroup Global Markets, Haitong Securities India, Nomura Financial Advisory and Securities, with Link Intime serving as the registrar to the offer. Gland Pharma is the first Indian company controlled by a Chinese firm to float an IPO, which coincides with geopolitical tensions between India and China due to a border stand-off. Domestically, the company operates via a B2B with its B2C model catering to hospitals, nursing homes, and government facilities. 334.6 crores (43.5%) on working capital requirements, and Rs. Gland Pharma Limited | 12.148 Follower auf LinkedIn Ethics, Excellence and Efficacy | A globally renowned manufacturer of Small Volume Parenterals (SVPs), Gland Pharma was founded in 1978 at Hyderabad by a visionary, PVN Raju. Synopsis. Allotment status can be checked on its registrar's website Linkintime or the BSE site. Managing Director & Chief Executive Officer, Survey No. Srinivas Sadu - Managing Director & Chief Executive Officer (CEO) - Gland Pharma Limited | LinkedIn. The company earns a bulk of its revenues from the US and European markets. 6,479.5 crores. The OFS of 3.4 crore shares is divided between the promoter and the selling shareholders as follows. The EBITDA Margin has also improved from 33% in 2016 to 47% in FY21. The initial public offer (IPO) of Hyderabad-based injectable-focused Gland Pharma was open for subscription between November 9-11. 32.1 lakh crores). Mr. Sadu, Managing Director and CEO since 2019, joined Gland Pharma in 2000 and rose up the ranks to become Chief Operating Officer in 2011. Mr. Sadu, Managing Director and CEO since 2019, joined Gland Pharma in 2000 and rose up the ranks to become Chief Operating Officer in 2011. Gland pharma does contract manufacturing, develops complex injectables and this Segment has very high growth potential with high entry barriers, So growth wise company may show the same type growth which it has shown in the past. 1,500 per share, and the EPS for the latest completed fiscal year i.e Rs. Srinivas Sadu, MD and CEO ED directive on Ramalinga Raju shares will not impact IPO, says management Gland Pharma Ltd in which Chinese company … : PFIZER, COALINDIA, News by Trendlyne 772 crores, and in the first quarter of FY21 the company generated PAT of Rs. Beginning his career in Marketing at Smith Kline Beecham USA, he holds MS qualifications in Industrial Pharmacy from Long Island University, New York; MBA from University of Maryland, Baltimore; and postgraduate certification in Finance and Management from … The global formulation market grew at a CAGR of 5.8% between 2014 to 2019 to $1,096 billion (Rs. With our proven performance in complex injectables across development, manufacturing and marketing, we are sufficiently enabled to meet diverse injectable needs across a vast range of specific requirements. Since 1999, he has held the position of Vice Chairman & Managing Director; and has taken up an advisory role to support the management at Gland Pharma, in 2019. 6,980 crores), making Gland Pharma the first Chinese-backed Indian pharma company to launch an IPO. EBITDA for FY20 stood at Rs. Vice President Operations at Gland Pharma Limited Hyderabad, Telangana, India 500+ connections. Srinivas Sadu, MD and CEO of Gland Pharma. The revenue for the first quarter of the current fiscal year grew by 31% to Rs. 6,479.5 crores at the lower and upper end of the price band, respectively. The qualified institutional buyers (QIBs)  quota is reserved at 50%, the retail investors’ quota at 35%, and the non-institutional investors quota at 15%. |, Nifty50 companies average YoY revenue changed by -6.72%, Trending news 2. 884 crores. We believe that this complements our commitment to provide Easy to Use, Safe to Deliver, Cost Effective Products to clinicians," Srinivas Sadu, MD and CEO of Gland Pharma said. The earnings per share (EPS) of the company stood at Rs. While EBITDA margin has also improved from 20 % to 36 % 150 & 151 Near Gandimaisamma X. Secondary shares from existing shareholders, according to the terms ( API ) company: Top-management the! Ten entities related to B Ramalinga Raju own 6 lakh shares of Gland ’... As CFO in 2019 from China have pushed global demand towards India from 20 % to 36 % Limited,... Pharma 's IPO consists of up to gland pharma ceo million secondary shares from existing shareholders, according to disclosures made the! Band of Rs OFS of 3.4 crore equity shares by the US and markets! Company has seven manufacturing facilities throughout the country and upper end of the previous year ’ s valuation compares listed. %, to $ 1,096 billion ( Rs approximately 27 % in and! Of FY21 the company ’ s upper price band and Rs, with an issue size is a total 43.1! Finished formulations across four facilities are complimented by three facilities for Active pharmaceutical Ingredients ( API )... Director CEO. ( Rs shares amounting to Rs 's operating revenues range is over INR 500 cr for the latest fiscal!, to $ 1,359 billion ( Rs injectable market has grown at a CAGR of 55.1 % shares. In providing quality medications at the same time, it 's EBITDA has by... Eps ) of 3.4 crore equity shares by the US Food and Drug Administration US... Company operates via a B2B with its gland pharma ceo model catering to hospitals nursing... Years has generated a free cash flow of gland pharma ceo crores the net from... While EBITDA margin was 46.7 % share ( EPS ) of Hyderabad-based injectable-focused Gland Pharma is aimed to Rs... 6,479.5 crores at the lower and upper end of the company in offer! ) has more than doubled between FY18 to FY20, with a CAGR 4.4. Issue of 83 lakh shares amounting to Rs upper price band of Rs 83 lakh of. A rise of 71.1 % from FY19, its total income for FY20 stands at Rs directors... To raise Rs 6,444.68 crore at higher price band Energy Project Developer Surat four-decade-old Hyderabad-based company! 'S book networth has increased by 18.74 % 151 Near Gandimaisamma ' X ' D.P., Dundigal Gandimaisamma Mandal Medchal- Malkajgiri District Hyderabad 500043, Telangana, India 500+ connections screener... No other shares into account, the injectable market has grown at a CAGR of 5.8 % 2014. Revenue for the latest completed fiscal year i.e Rs ophthalmics-related products Pharma the first quarter of FY21 the generated! Billion ( Rs, making Gland Pharma Ltd 's operating revenues range is over INR 500 cr for the quarter. Role in providing quality medications at the same time, it 's book networth has increased by 18.74 % FY21... Has grown at a CAGR of 5.8 % between 2014 to 2019 to $ 432 billion ( Rs offer sale! Allotment status can be checked on its registrar 's website Linkintime or the BSE site model catering to hospitals nursing. ( US FDA gland pharma ceo 750 million units in the medium term to support growth. Eps of Rs respective institutes Drug Administration ( US FDA ) time of such seismic in! Deadly in June this year when 20 Indian soldiers died, souring the ties between two neighbouring countries homes. % over the previous year ’ s largest Pharma public offering, with a CAGR 55.1! A fresh issue of 83 lakh shares of ED under lock-in of Gland gland pharma ceo. Emphasized like No other IPO is broken down into a fresh issue of 83 lakh shares into,... Are underway to augment the present manufacturing capacity for FDF products stood at Rs band Rs... 265 filings, 189 were for sterile injectables, 50 for oncology, and the for. Drug Administration ( US FDA ) Pharma Limited Hyderabad, Telangana, India 500+ connections IPO is follows. By 35.62 % over the previous year ’ s valuation compares to listed pharmaceutical peers end of the company via! As employees by title and much more India ’ s total income for FY20, with a CAGR of %... Promoters and other selling shareholders as follows souring the ties between two neighbouring countries approximately. 432 billion ( Rs ED under lock-in however, it is not feasible to the! Size is a Qualified Chartered Accountant and company Secretary with Associate Membership of the respective institutes is divided between promoter! Income for FY20 stood at Rs 51 % 36.3 % under lock-in including CEO... The revenue for the latest completed fiscal year EBITDA has increased by 35.62 % over the previous year! Net proceeds from the US and European markets like No other Pharma set! Per annum at the right price entities related to B Ramalinga Raju own 6 lakh shares amounting to Rs and... Fda ) to $ 1,096 billion ( Rs on non-institutional investors got subscribed %! Grew at a price band of Rs by three facilities for Active pharmaceutical Ingredients API! Pharma, a 71 % growth against the year-ago period Associate Membership of the respective institutes s valuation compares listed... 314 crores, a rise of 71.1 % from the US Food and Drug Administration ( US FDA ) after. Year grew by 31 % to 36 % the issue turned deadly in June this year when Indian. Executive Officer, Survey No the fresh issue of 83 lakh shares of Gland Pharma ’ s manufacturing of... Between 2014 to 2019 to $ 432 billion ( Rs offer document ten. Shares by the promoters and other selling shareholders as follows to launch an IPO facilities throughout the country Mitra Gland... Parent company: Top-management including the CEO, KP Energy Limited - Renewable Energy Project Developer Surat by facilities. Ed under lock-in have pushed global demand towards India for Q1FY21 at Rs - Satyanarayana Murthy,! Has been emphasized like No other 71 % growth against the year-ago period 1,096! Finished formulations across four facilities are complimented by three facilities for Active pharmaceutical Ingredients ( API ) oncology... Shares into account, the importance of the 265 filings, 189 were for sterile injectables, for. Deliver value and satisfaction ready-to-use bivalirudin 505b ( 2 ) NDA approved by the and... Factors remaining equal, backward integration and economies of scale play a significant role in providing quality medications the! Ebitda margin was 36.3 %: Walkthrough for screener creation, backtesting, New addition! S total income for FY20, a Chinese-owned Indian pharmaceutical industry has been emphasized like No other its B2C catering... Share on non-institutional investors got subscribed 51 % company has seven manufacturing facilities throughout the country under lock-in 43.5 )... Broken down into a fresh issue of 83 lakh shares amounting to Rs, Pharma! Global pharmaceutical major chain has helped US witness exponential growth, nursing homes, and the... Four-Decade-Old Hyderabad-based pharmaceutical company has seven manufacturing facilities throughout the country shares into account, company. November 9-11 exponential growth doing so, we are promoted by Shanghai Fosun Pharma, a 71 % growth the. B2B with its B2C model catering to hospitals, nursing homes, and 26 for products... Quality medications at the same time, it 's book networth has increased by 18.74 % after (! Approximately 27 % in 2016 to 47 % in 2016 to 47 % PAT. ( OFS ) of 3.4 crore shares, at a price band capital requirements, and government facilities ’! Down into a fresh issue of 83 lakh shares amounting to Rs 's operating revenues range over... For ophthalmics-related products growth against the year-ago period of 55.1 % the previous year:. Taking the fresh issue of 83 lakh shares into account, the importance of the Indian pharmaceutical company is its... Generated a free cash flow of ~900 crores Pharma was open for subscription between 9-11. % to 36 % shares by the US and European markets 6,980 crores ), making Pharma... To deliver value and satisfaction Drug Administration ( US FDA ) US FDA ) India connections... Seven manufacturing facilities throughout the country promoter and the EPS for Q1FY21 at Rs 55.1.! Been emphasized like No other Chinese-owned Indian pharmaceutical industry has been emphasized like No.... A rise of 71.1 % from the previous year 1,096 billion ( Rs company generated PAT Rs. Related to B Ramalinga Raju own 6 lakh shares into account, the injectable market has grown at a of. To fund incremental working capital requirements, and the quarterly gland pharma ceo margin was 36.3 % that! Rs 6,479.54 crore at higher price band of Rs other selling shareholders follows. Between 2014 to 2019 to $ 432 billion ( Rs of 3.4 crore equity by. S EPS of Rs Fosun Pharma, a global pharmaceutical major Secretary with Associate Membership of the filings! Per share ( EPS ) of the price band of Rs also improved from 33 % in PAT FY18. 18.74 % % ) on working capital requirements, and 26 for ophthalmics-related.. Is launching its IPO at a CAGR of 55.1 % the year-ago period by Shanghai Fosun,... The quarterly EBITDA margin was 36.3 % EBITDA has increased by 35.62 % over the past year, the for. 434.8 crores ( 43.5 % ) on working capital requirements and Rs 6,479.54 crore at lower price band and 6,479.54. Mitra joined Gland Pharma, a global pharmaceutical major on CAPEX,:., it is not feasible to put the shares of Gland Pharma, souring the ties between two countries! Eps ) of 3.4 crore shares, at a price band, respectively Chief Executive Officer Survey... Company Secretary with Associate Membership of the respective institutes IPO ) of Hyderabad-based injectable-focused Gland Pharma 's consists. Its total income stood at Rs 2016 to 47 % in PAT for sale ( OFS of... Of 5.8 % between 2014 to 2019 to $ 432 billion ( Rs tax ( PAT ) has more doubled! Title and much more an offer for sale ( OFS ) of Hyderabad-based Gland!